Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286375 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL3286721 | 0.79 | MAPT (0.47) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL22833973 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2HSD17B10ALDH1A1MAPTRAB9A | |
| SCHEMBL29501621 | 0.74 | ALDH1A1 (0.56) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL5505676 | 0.73 | SMN1; SMN2 (0.52) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL4919115 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL3284326 | 0.70 | CRHR1 (0.33) | HSD17B10ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL27307252 | 0.68 | MAPT (0.39) | SMN1; SMN2HSD17B10ALDH1A1MAPTRAB9A | |
| SCHEMBL10991202 | 0.67 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT | |
| SCHEMBL1913640 | 0.67 | HSD17B10 (1.00) | SMN1; SMN2HSD17B10HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | SMN1; SMN2 2597/4885HSD17B10 2322/4885HTT 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.